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Abstract - We exploit the introduction of sulfa drugs in 1937 to identify the impact of 
exposure to pneumonia in infancy on later life well-being and productivity in the United 
States. Using census data from 1980-2000, we find that cohorts born after the introduction 
of sulfa experienced increases in schooling, income, and the probability of employment, and 
reductions in disability rates. These improvements were larger for those born in states with 
higher pre-intervention pneumonia mortality rates, the areas that benefited most from the 
availability of sulfa drugs. Men and women show similar improvements on most indicators 
but the estimates for men are more persistently robust to the inclusion of birth state specific 
time trends. With the exception of cognitive disabilities for men and, in some specifications, 
work disability for men and family income, estimates for African Americans tend to be 
smaller and less precisely estimated than those for whites. Since African Americans exhibit 
larger absolute reductions in pneumonia mortality after the arrival of sulfa, we suggest that 
the absence of consistent discernible long run benefits may reflect barriers they encountered 
in translating improved endowments into gains in education and employment in the pre-
Civil Rights Era. 
 
Keywords: early childhood, infectious diseases, pneumonia, medical innovation, antibiotics, 
schooling, income, disability, mortality trends 
JEL codes: I18, H41 
 
Acknowledgements – We would like to thank Douglas Almond, Tania Barham, Winnie Fung, 
Adriana Lleras-Muney, Alice Mesnard and participants at the 2010 American Society of Health 
Economists conference, the 2010 ISI Delhi conference, the 2011 American Economic Association 
conference, the May 2011 NBER Children’s Meeting and at seminars at the Universities of London 
and Florence and at the Departments of Social Medicine and Economics at Bristol for helpful 
comments. We are grateful to Anne Case, Adriana Lleras-Muney, and Grant Miller for providing 
access to their historical US data, Sarah Karlsberg Schaffer for her efforts in extending this historical 
database and Eddy Tam for excellent comments and help with the data. All errors are our own.   0
 
Is The Captain of the Men of Death Still At Play?   
Long-Run Impacts of Early Life Pneumonia Exposure during the Sulfa Drug 
Revolution in America 
 
Sonia Bhalotra and Atheendar Venkataramani 
 
1. Introduction 
Infections are the leading cause of child mortality in developing countries, as they 
were in developed nations until the middle of the 20th century (Black, Cousens, Johnson, 
Lawn, Rudan, Bassani et al., 2010; Cohen, 2000). In addition to causing disability and death 
in the short-run, infectious diseases in early childhood may also lead to worse health and 
socioeconomic outcomes later in life. Immune responses to infections claim nutritional 
resources which, in the young, tend to be diverted away from physical and mental 
development. In this way, severe or repeated infections could lead to long-term “scarring” 
expressed as poorer health and lower cognitive development in adulthood (Crimmins & 
Finch, 2006; Gluckman & Hanson, 2005). In addition, if there are dynamic 
complementarities in early age inputs, any particular damage in infancy may translate into 
multiplicative deficits later in childhood and into adulthood (Heckman, 2007). These 
processes suggest that wellbeing and productivity in today’s population may, to a degree, 
have their roots in disease and treatment conditions that prevailed a generation or more ago.  
This paper focuses upon pneumonia in early 20
th century America, investigating 
whether birth year exposure had impacts on indicators of human capital that persist into 
adulthood and are discernible at the population level. In the 1930s, the disease accounted for 
1 of every 10 deaths in the United States and was the leading cause of infant mortality in 
infancy (Linder & Grove, 1947; Wegman, 2001). In today’s developing countries, pneumonia 
is similarly the dominant cause of child mortality (Bhutta, 2007; Black et al., 2010), 
accounting for 20 to 30 per cent of childhood deaths, two thirds of which occur in infancy 
(Bang et al. 1990, Kirkwood et al. 1995). We focus on birth year exposure in view of 
evidence that morbidity and mortality from pneumonia were both far more severe in infancy 
than at any other age (section 2 below). Moreover, infancy is a time when growth is rapid, 
nutritional demands are high, and developmental plasticity is greatest. For these reasons, 
infections in the birth year are most likely to create irreversible damage.    1
Identification of causal effects of early life infections on later life attainments is 
challenged by likely selectivity into infection. We overcome this problem by investigating 
exogenously determined declines in infectious disease exposure generated by the sudden and 
plausibly exogenous arrival of sulfonamide antibiotics (sulfa drugs) in the United States in 
1937. These agents were the first clinically available antibiotics and they were quickly utilized 
to treat a variety of infections leading to sharp decreases in both morbidity and mortality 
from pneumonia (Greengard, Raycraft, & Motel, 1943; Jayachandran, Lleras-Muney, & 
Smith, 2010; Lesch, 2007). Our study investigates whether this short run pattern is mirrored 
in longer run outcomes including education, income, employment and disability recorded in 
Unites States census data for 1980-2000. Our research strategy exploits variation across 
states in the pre-intervention level of pneumonia, across diseases in their treatability with 
sulfa drugs and also across age of exposure. 
We find discontinuous improvements across the named outcomes for cohorts born 
post-sulfa. These improvements are increasing in the pre-intervention level of the 
pneumonia mortality rate, consistent with states with an initially higher burden of 
pneumonia benefiting more from the new antibiotics in terms of absolute reductions in 
pneumonia mortality (see Bleakley 2010).  The estimates for both men and women are of 
similar size and, in each case, robust to including a vector of controls that allow a similar 
discontinuity in 1937 for a range of communicable and non- communicable diseases that 
were not responsive to sulfa. They similarly stand up to controls for sulfa-induced changes in 
maternal mortality that arose from control of puerpal sepsis, illustrated in Jayachandran and 
Lleras-Muney (2009). Adding in controls for income, education and health infrastructure in 
the birth state and birth year renders schooling and disability improvements for women 
insignificant and adding state specific trends to this already rich specification diminishes all 
of the coefficients for women, driving them to insignificance. The results for men are 
remarkably robust. In an extension we estimate a triple difference that exploits the steep 
gradient in infection risk between infancy and age fifteen, leading us to expect larger long 
run benefits for individuals who were infants when sulfa arrived than for individuals who 
were fifteen at the transition. Interestingly, while the estimates for men continue to hold 
steady, the estimates for women are strengthened. The coefficients for education, 
employment and income are now robust to state trends and cohort-region fixed effects.    2
The estimates for African-Americans are more imprecisely estimated and more 
sensitive to specification than for whites. There is nevertheless some evidence that disability 
reductions were larger amongst blacks. For black men, the coefficients for cognitive 
disability in the basic model and for work disability in the triple difference model are larger 
t h a n  f o r  w h i t e  m e n .  I n  t h e  m o d e l s  w i t h  c ontrols for time-varying unobservables, the 
socioeconomic outcome coefficients are smaller for blacks. This is despite the fact that 
blacks experienced larger absolute reductions in pneumonia mortality rates with the arrival 
of sulfa drugs. We propose that these findings may reflect more limited opportunities for 
blacks to translate improved health endowments into human capital and socioeconomic 
returns in the pre-Civil Rights Era. Pursuing this hypothesis further is an interesting area for 
future research.  
We investigate and in general establish robustness of the reported findings to 
lifecycle effects on outcomes, mean reversion in outcomes, choice of sample window and 
race-specific rather than race-averaged state mortality series. We non-parametrically examine 
variation in age of exposure and this confirms that long run outcomes are most sensitive to 
pneumonia exposure in infancy. We argue that the estimated impacts are large (sections 5.1, 
5.4).  
Our research relates to a wider literature concerned with the origins of socio-
economic inequality in early childhood. Much of this literature is focused upon parental 
attitudes and resources and their impact on the formation of cognitive and non-cognitive 
skills that ultimately determine education, employment and income (Flavio Cunha and James 
Heckman, 2009, James Heckman, 2007, Sandra Black and Paul Devereux, 2010). Our study 
contributes to an emerging strand that focuses upon the importance of early life health as a 
potential determinant of human capital development (Currie, 2007, Almond and Currie 
2010). A few previous studies in this strand examine the long run impact of infectious 
diseases. (Almond, 2006) (Kelly, 2009) use the influenza pandemics of 1918 in the US and 
1957 in the UK as natural experiments to identify long run human capital effects of in utero 
exposure.
1 (Bleakley, 2010; Cutler, Fung, Kremer, Singhal, & Vogl, 2010; Lucas, 2010; 
Venkataramani, 2010) utilize the introduction of large scale eradication campaigns to 
                                                 
1 In these pandemics, unusually, infection rates peaked amongst women of childbearing age. 
Influenza (and pneumonia) infections do not transmit across the placenta, so the identified impacts 
flow from the mother’s contracting the infection and the consequent impoverishment of her 
nutritional reserves.   3
examine the long-run effects of childhood malaria exposure on earnings, schooling and 
cognition later in life.  
This paper makes the following contributions to the literature. We provide the first 
estimates for pneumonia, which despite being the leading cause of childhood mortality in the 
developing world has drawn relatively little attention from researchers and policy makers. In 
contrast to diarrhea, which has shown substantial declines, there has been limited progress in 
controlling pneumonia in the last two decades (Bhutta, 2007). The pandemic conditions and 
(near)-total eradication campaigns examined in previous studies are dramatic events that may 
have had different long-term effects than more subtle changes in the disease environment.
2 
It is therefore unclear whether these findings can be applied to other policies or contexts. 
We focus on reductions in infectious disease morbidity and mortality rates arising from 
therapeutic measures rather than preventive measures. The long run evidence we offer is 
hence unique in complementing short run evidence of benefits of treatment of childhood 
pneumonia with antibiotics (Bang et al. 1990). Failure to recognize longer run benefits will 
tend to lead to sub-optimal levels of investment in drug treatments. More specifically, we 
provide what appear to be the first estimates of the long run returns to biomedical 
innovation. Hence our findings motivate investment in medical research and changes in 
extant patent laws and marketing structures to help promote the distribution of 
pharmaceuticals, such as antibiotics, at affordable prices in the developing world. On the 
prevention side, the long-run scarring effects noted in this study should increase interest in 
large scale roll-outs of pneumococcal vaccines, which have shown to be highly efficacious in 
reducing pneumonia incidence and mortality in developed and developing countries alike 
(Cutts, Zaman, Enwere, Jaffar, Levine, Okoko et al., 2005). 
The rest of the paper is laid out as follows. Section 2 discusses the sulfa drug 
revolution and its effects on pneumonia mortality and morbidity in the United States. 
Section 3 sets out our research strategy, and Section 4 describes the data. Section 5 presents 
the results and Section 6 concludes. 
 
2. Pneumonia and the Sulfa Drug Revolution 
                                                 
2 Influenza mortality increased four-fold during the flu epidemics analysed while the sulfa-induced 
decline in (infant) pneumonia mortality rates was 30%. So epidemic infection rates are some orders 
of magnitude larger than endemic rates and it is plausible that there are no effects on long run 
outcomes below some threshold level of infection.   4
Pneumonia is an inflammatory disease of the lung that is most often caused by 
infectious agents such bacteria and viruses. In the 1930s, pneumonia accounted for 10% of 
all-age deaths in the United States and about 44% of neonatal deaths.
3 The underlying 
incidence of pneumonia was high as well though this is more difficult to pin down because 
of patchy and unreliable data. Estimates from the US National Health Survey conducted in 
1934-1936 show a nationwide morbidity rate of 3 cases per 100 infants, with rates potentially 
twice as high among the poor and those living in crowded conditions (Britten, 1942). 
However, it is likely that this represents a significant (at least two-fold) underestimate of the 
true pneumonia burden (Klugman & Feldman, 2009). Data from an outpatient population in 
North Carolina, a state that lay in the middle of the pneumonia mortality distribution in the 
1930s, gathered during the mid-1980s suggests an incidence rate of nearly 10 per 100 
children under the age of 1 year (Denny & Clyde, 1986). Overall the infection rate was 
probably about 6% on average and as much as 12% in more affected states and more 
affected groups. In today’s developing countries it is estimated that there are 28 pneumonia 
cases per 100 children under the age of 4 each year (Rudan, Tomaskovic, Boschi-Pinto, & 
Campbell, 2004).  
Prior to the arrival of sulfa drugs, pneumonia was primarily treated with supportive 
care. In the early 1930s, a small but growing number of clinicians began to use intravenous 
serum therapy to combat bacterial pneumonia, which was often more severe and conferred a 
higher risk of death than its viral counterpart (Lesch, 2007).
4 Serum therapy was an 
expensive and time-intensive process restricted to hospitalized patients. There was 
nevertheless some clinical evidence of its effectiveness in reducing pneumonia mortality rates 
(Finland, 1960).  
The antibiotic properties of sulfonamides were first noted in 1932 by German 
chemists conducting experiments on textile dyes. Evidence of their anti-microbial potential 
was first published in 1935 and confirmed in clinical trials conducted in the following two 
                                                 
3 Young children tend to be more vulnerable to contracting and sustaining infections such as 
pneumonia because their immune systems are underdeveloped. The all cause neonatal mortality rate 
per 1000 births in 1930 was 3.6 and mortality from pneumonia was 1.6. By 1940 these rates had 
dropped to 2.4 and 1.1 respectively (US vital statistics).  
4 This involved obtaining antibodies from animals that were infected with a specific microbe. Serum 
refers to the component of animal blood comprised of fluid and antibodies, which has to be 
separated from the cellular component. The serum was injected intravenously into human patients, 
where the antibodies from the animal would bind to the infectious agent and aid the endogenous 
immune response (Lesch, 2007).    5
years (Gibberd, 1937; Jayachandran et al., 2010; Kiefer, 2001; Lesch, 2007; Long & Bliss, 
1937). A December 1936 New York Times article lauded the potential benefits of sulfa and, 
by early 1937, the drugs became widely available in the United States. They were relatively 
inexpensive and heavily promoted, leading to a “sulfa craze” that lasted until the arrival of 
the first penicillins in 1942-44.   
The arrival of sulfa drugs represented a tremendous boon to clinicians treating 
pneumonia. The first sulfa agents, such as Prontosil, were only somewhat effective against 
Streptococcus pneumonaie, the agent responsible for the majority of bacterial pneumonias. 
However, in 1938, sulfapyridine (also known as M&B 693), became available for clinical use. 
Clinical trials, conducted soon after sulfapyridine became available showed striking 
reductions in pneumonia case fatality rates among inpatients (Evans & Gaisford, 1938; 
Gaisford, 1939; Lesch, 2007). Within months after its introduction, the use of sulfapyridine 
for treating pneumonia became widespread. 
In addition to the benefits noted in small clinical trials, the arrival of sulfa drugs had 
large impacts on mortality from pneumonia at the population level. Using state and national 
time series data for the United States, Jayachandran, et al (2010) demonstrate structural 
breaks in the time series data for mortality from sulfa treatable diseases around the time the 
drugs first became available. They attribute 17-32% of the post-1937 decline in pneumonia 
to the arrival of sulfa drugs.  
Figure 1, which plots national pneumonia mortality rates between the years 1930 and 
1943 illustrates these findings nicely. Prior to the arrival of sulfa, pneumonia rates held 
steady, suggesting that serotherapy had little impact on population level pneumonia mortality 
rates. As shown in the figure, the death rate began to drop in 1937 (though it still was higher 
than in the 1930-1935 period) and then fell sharply in 1938 and thereafter. This pattern is 
consistent with the arrival of sulfa drugs better suited to combat pneumococcal bacteria in 
1938.  Figure 2 examines the post-sulfa absolute reduction in pneumonia mortality as a 
function of birth state pre-sulfa pneumonia mortality rates. This shows convergence in 
pneumonia mortality across states after 1937, confirming our prior that states with a greater 
initial burden of disease from pneumonia gained most from the arrival of sulfa drugs. As 
discussed in the next section, the patterns in Figures 1 and  2 form the basis of our 
identification strategy.    6
Because our goal is to examine the long-run impacts of pneumonia exposure, it is 
important to explicitly examine the effects sulfa drugs on pneumonia morbidity, as well as 
mortality, at the population level. If the advent of sulfa only saved the lives of those with 
severe cases of pneumonia, our long-run impact estimates may simply reflect the effects of 
reduced mortality selection owing to the therapeutic intervention rather than the effects of 
scarring from the underlying disease. However if sulfa therapy (additionally) reduced the 
severity and incidence of pneumonia episodes across the population, we would be better 
placed to investigate our hypothesis that childhood exposure to the disease scarred 
adulthood outcomes for survivors. 
There is, in fact, compelling evidence to suggest that the advent of sulfa drugs led to 
reductions in the severity of pneumonia episodes. With respect to hospitalized patients, a 
number of clinical trials on infants and children from the era cite rapid improvements in 
fever, mental status and other physical examination findings, illustrating that the average 
inpatient case of pneumonia was shorter in duration and followed a less severe course as a 
result of sulfa chemotherapy (Greengard et al., 1943; Hodes, Stifler, Walker, McCarty, & 
Shirley, 1939; Moody & Knouf, 1940; Smith & Nemir, 1939). Data on industrial workers 
illustrate a 20-30% reduction in the number of illness days after the arrival of sulfa drugs 
(Ungerleider, Steinhaus, & Gubner, 1943). Along the same lines, comparisons of US Army 
experiences between the first and second World Wars also suggest that sulfa drugs were 
instrumental in drastically reducing the severity of and infirmity time from pneumonia 
among case soldiers (Lesch, 2007). Similar benefits were noted for outpatients, who 
accounted for around 70% of all pneumonia cases (Britten, 1942). Sulfa drugs were widely 
available to, and utilized by, laypersons and community physicians soon after their arrival in 
the US (Lesch, 2007). Thus, it is likely that pneumonias treated in the community would be 
less severe and shorter in duration than in the absence of antibiotic therapy and less likely to 
warrant hospitalization. This is relevant to analysis of race differences since it suggests that 
even if black people faced barriers to hospital access, they could access sulfa drugs.  
Regarding the incidence of pneumonia, in theory it is possible that antibiotic therapy 
could reduce the probability of contracting pneumonia since those undergoing treatment 
may produce fewer respiratory secretions and therefore be less contagious. That said, 
incidence rates in the sample of industrial workers alluded to above did not appear to decline 
once sulfa-drugs became available (Ungerleider et al., 1943). However, as measures of   7
pneumonia incidence are sensitive to improvements in surveillance and diagnosis, it is 
difficult to draw firm conclusions from the available data. As such, while we can state 
confidently that sulfa drugs led to noteworthy reductions in the length, severity and risk of 
death from pneumonia, we do not have reliable evidence on whether they led to reductions 
in the probability of contracting the infection altogether. In this regard, it is useful that we 
estimate population-averaged effects. 
Since the arrival of sulfa drugs sits at the crux of our identification strategy to 
examine the long-run impacts of pneumonia, it is worth discussing why we are less 
concerned with the long-run impacts of other sulfa treatable conditions. Treatable diseases 
other than pneumonia for which consistent time series data are available and analyzed by 
Jayachandran et al (2010) are scarlet fever and maternal mortality from puerperal sepsis. 
These authors show that while the arrival of sulfa led to larger relative declines in these 
conditions, they accounted for only 0.2 and 1% respectively of total all-age mortality. In 
contrast, nearly 10% of all-age mortality was attributable to pneumonia. Moreover, in the 
pre-sulfa era, morbidity and mortality from pneumonia was concentrated among infants and, 
outside of congenital conditions, pneumonia was the leading cause of neonatal and infant 
death. Scarlet fever was at best a minor cause of morbidity or mortality in infants and is 
therefore not germane to an analysis of the long-run effects of early childhood disease.  
However, the decline in maternal mortality induced by sulfa may well have 
influenced long-run outcomes for children born at the time, to allow for which we control 
for sulfa-induced reductions in maternal mortality as discussed in the next section. At the 
population level, parents may perceive greater returns to early life investments in girls when 
maternal mortality rates are lower, potentially leading to improvements in long-run outcomes 
for women vis-a-vis men (Jayachandran and Lleras-Muney 2009). At the individual level, 
changes in the risk of one’s own mother dying and in family size may have influenced 
investments in both boys and girls. Family size impacts can arise because of changes in the 
probability of infertility, a potential complication of post-partum fever. Quantity-quality 
tradeoffs and/or sibling competition models imply reduced investments in the index birth, 
so diluting the impact of long-run gains from the other mechanisms. It is important to note 
that these effects are necessarily indirect because maternal post-partum infections are not 
transmitted to infants. As such, examining the effects of maternal mortality declines would 
provide little information on the long-term effects of infectious disease in early childhood.    8
 
3. Research Strategy 
  We utilize the plausibly exogenous availability of sulfa drugs, along with the fact 
that areas with higher mortality from pneumonia mortality rates experienced greater returns 
from the new therapies to identify the long-run effects of birth year exposure to pneumonia. 
The baseline model is 
 
Yrstc = α + β*postt*base_pneumonias + δs + ζt + γr + μc + θrs + ηrt + λrc + erstc    
       
Ygrstc denotes the outcome of interest for individuals of gender (g), race (r), birth state (s) and 
birth year (t) for whom outcomes are observed in census year (c). Since Jayachandran et al. 
(2010) test for structural breaks in the mortality series and identify 1937 as the break 
associated with sulfa, we define postt = 1 for birth cohorts 1937 and after. The pre-sulfa 
pneumonia mortality rate in the birth state is denoted base_pneumonias and we use this to 
proxy for pre-sulfa pneumonia exposure. A similar strategy is employed in (Acemoglu & 
Johnson, 2007; Bleakley, 2007; Lucas, 2010). The Greek letters represent race-specific fixed 
effects for birth state, birth year and census year.  The standard errors are clustered at the 
birth state level to account for serial correlation in the outcomes (Bertrand, Duflo, & 
Mullainathan, 2004) and regressions are weighted by cellsize
5.  
The outcomes we initially examine are years of schooling (highest year of education 
completed), logged household income (total pre-tax income owned by a family unit), 
employment status and work limiting or preventing disability. We then extend the analysis to 
investigate cognitive and physical disability (and, forthcoming: personal income and poverty 
risk). We restrict our analysis to the time period 1930-1943 in order to reduce the possibility 
of confounding from other public health events or interventions, for example, the influenza 
epidemic of 1928-9 and the increasingly widespread use of penicillin after 1943.
6 Our use of 
multiple census years allows us to observe the same birth cohorts at different ages and so to 
identify cohort effects as distinct from life cycle effects. It also increases the precision of our 
estimates.  
                                                 
5 The substantive results remain unchanged even if cell-count weights are not used. 
6 Any direct impacts of World War II will be absorbed by the year dummies. We nevertheless 
examined and established robustness of the estimates to truncating the post-sulfa period at 1941, 
after which the US got involved in the war.   9
Unobserved heterogeneity at the birth state and birth year level 
The main threat to inference with this sort of differences-in-differences model is the 
potential play of unobservables that vary by birth state and birth year and are correlated with 
both declines in pneumonia and the outcomes. To address this, we investigate sensitivity of 
the results to a variety of controls reflecting health and socioeconomic conditions in the 
birth state and birth year. For example, post may pick up coincident factors other than sulfa 
drug availability that led to sudden improvements in health. A powerful check against this is 
to use information on trends in diseases that were not treatable with sulfa drugs, so invoking 
what is loosely a third difference across cause of death. The premise is that the impact of 
other factors on mortality trends would not have discriminated between sulfa-treatable and 
sulfa-untreatable diseases. We interact post with the base (pre-sulfa) level of birth state specific 
mortality rates from tuberculosis, under-2 diarrhea, heart disease and cancer. The 
communicable diseases help control for state specific changes in sanitation, public health 
programs, housing (etc) that may have coincided with the arrival of sulfa. The inclusion of 
non-communicable diseases is expected to further control for factors such as health care 
quality and access. In exploiting information on diseases that were and were not treatable 
with sulfa drugs, we mirror in our state level analysis of long run outcomes the approach 
taken by Seema Jayachandran et al. (2010) in their aggregate analysis of short run changes in 
mortality rates. We add to the “untreated” diseases in their sample diarrhea mortality as this 
is available for the under-2 population and our focus is on early life exposure to infection. In 
other words, we expect diarrheal mortality rates to help capture unobserved improvements 
in conditions specific to young children. 
Importantly, we also control for the pre-sulfa maternal mortality rate interacted with 
post. For reasons discussed in the previous section, this helps us isolate the impact of 
improved treatability of pneumonia. In addition to the vector of control disease mortality 
rates at the birth state-birth year level, we directly control for trends in birth state-birth year 
varying socioeconomic variables including logged state income per capita and the numbers 
of schools, hospitals and physicians per capita. To allow for any remaining pre-existing 
differences in trends we investigate specifications with birth state specific linear (and 
quadratic) time trends and census region* birth year fixed effects.  
The richer specifications may amount to “over-controlling.” For example, increased 
risk of infections from weakened immune systems as well as competing risks from different   10
conditions create population level correlations in disease rates. Thus, controlling for 
additional diseases may capture variation in disease trajectories that are in fact driven by the 
use of sulfa drugs rather than by unobserved confounding factors. As such, it is possible that 
the inclusion of such controls may produce estimates that in some sense obscure the true 
returns to reductions in pneumonia rates resulting from therapeutic innovation. Similarly, 
controlling for state trends is typically quite demanding of the data. We therefore present 
results with and without each set of controls.  
Other robustness checks detailed in the results section involve controlling for mean 
reversion in the outcome variables, testing sensitivity to the end points of the sample 
window and checking for whether lifecycle effects may be loading onto the estimated cohort 
effects. 
Age of exposure 
In an extension of the baseline (double difference) specification, we allow for returns 
to sulfa exposure at other ages in childhood. In contrast to Almond (2006) and Kelly (2009) 
we do not expect impacts from foetal exposure because mothers of childbearing age 
experienced very low infection rates (Britten 1942). However, even if vulnerability to 
contracting pneumonia declined after age one, it was considerable at age 1-5. To investigate 
this, we replace post with a vector of birth year dummies for every year in the sample. We 
graph the resulting coefficients and test for a sulfa-related break. This specification also 
provides a useful falsification test: the presence of breaks in the coefficients in years other 
than around 1937 may suggest that the patterns seen in the data may be due to some process 
other than the introduction of sulfa drugs. Similarly, because the first sulfa drugs were less 
effective for treating pneumonia than sulfapyridine, which was introduced in 1938 and 
became widely used by 1939, the sulfa effects, if there are any, should increase in magnitude 
over the period 1937-1939. We assess this with the coefficient plots.  
The plots confirm the gradient in long run impacts by age. This is consistent with the 
age profile of pneumonia morbidity and mortality. Infection rates at birth in the pre-sulfa era 
(1934-36) were eight to ten times as large as at age 15. The average number of days of 
disability suffered by patients with pneumonia peaked in childhood and reached a minimum 
in the age group 15-24 (Collins 1931, Britten 1942: Table 2). Consequently we expect limited 
if any long run benefits of sulfa to be evident for individuals who were exposed at age 15   11
compared with individuals exposed at birth. We use this to estimate a specification with a 
triple difference. 
Gender and race heterogeneity 
We consistently allow treatment heterogeneity by race and by race-gender. Males may 
have benefitted more from early life exposure to sulfa for biological reasons. Surveillance 
data from the mid-1930s show that they were 25% more likely to contract pneumonia than 
females as infants (Britten, 1942). Males also tend to be more vulnerable to disease and early 
childhood shocks (Gluckman & Hanson, 2005; Low, 2000; Waldron, 1983) and so may incur 
more scarring from a given level of disease. The estimated impacts may however have been 
moderated or exaggerated by gender-specificity in the sensitivity of parental investments to 
health endowments. There is some evidence of a pro-male bias in contemporary times in the 
United States (Dahl & Moretti, 2008; Stanley & Jarell, 1998), which leads us to expect a 
stronger association between endowments and investments for females.  
The pre-sulfa black pneumonia mortality was about twice as high as that for whites 
(US Vital Statistics). This alone suggests black people will have benefited more from the 
arrival of sulfa. However this may be turned around if they either had more limited access to 
sulfa drugs (Seema Jayachandran et al. 2010, Doug Almond, Ken Chay and Michael 
Greenstone 2006) or if they had more limited opportunities to translate their improved 
endowments into improved socioeconomic status.  
 
4. Data 
Data for the outcome variables were taken from the 1980, 1990, and 2000 5% samples of the 
United States Census (see Data Appendix for further details). The marginal sulfa cohort (i.e., 
those born in 1937) were 43, 53, and 63 years old at the time of each of these enumerations, 
respectively. We calculated means for each outcome by birth state, birth year, census year, 
race and gender and used the cell means in the regression analysis
7. We estimated the 
equations by census year and found little evidence of lifecycle effects: estimates of pre/post 
sulfa cohort differences in outcomes were robust to observing the (marginal) cohorts at 
different ages. In addition, if sulfa exposed individuals who achieved fewer years of 
education were also likely to die later, then including data from later censuses may create a 
                                                 
7 The use of micro-level data produced very similar point estimates and standard errors. These results 
are available in the online appendix.   12
downward bias in the estimated impact of sulfa drugs. We find no significant evidence of 
this. For schooling, we similarly confirm that the estimates are very similar if we include the 
three census years but the estimates we report are based upon data from the 1980 census 
because the education variable is coded **************. We investigate indicators of physical 
and cognitive disability which are only available in the 2000 census. To avoid measurement 
error, we dropped cells in the bottom 1% of the cohort size distribution (i.e., those with less 
than 50 persons).
8  
Data on all-age disease-specific mortality rates (expressed per 1,000 people) are from 
the US Vital Statistics and were gathered by Grant Miller, Adriana Lleras-Muney and Anne 
Case and supplemented by us. Information on the socioeconomic characteristics of states 
come from sources detailed in the Data Appendix. For the period of interest, state-level time 
series data on pneumonia mortality are aggregated with influenza mortality, so we (like 
Jayachandran et al 2010) work with this compound variable. Combining mortality rates from 
these causes may lower measurement error, given that surveillance systems may have 
conflated influenza and pneumonia deaths and a large portion of influenza deaths came 
from secondary bacterial pneumonia. However influenza, being viral, was not responsive to 
sulfa drugs, while many types of pneumonia were. The availability of separate influenza and 
pneumonia mortality rates for certain years allows us to discern the contribution of 
pneumonia to the compound variable. Pneumonia dominated, accounting for 75% of all-age 
deaths (Jayachandran et al. 2010) and 89% of neonatal deaths (our estimates from the Vital 
Statistics) in the influenza plus pneumonia category. More importantly, there was little 
change in the influenza death rate between 1930 and 1940, suggesting that the reduction in 
mortality rates from both causes during in the period of interest was driven primarily by 
reductions in pneumonia mortality.
9 Table 1 provides descriptive statistics for each of the 
study variables.  
 
5. Results 
We first discuss estimates for schooling, family income, employment and work-
related disability. We then examine additional indicators of disability (and, forthcoming, 
                                                 
8 The results are unchanged even if these cells are included in the analysis. 
9 Between 1930 and 1940 neonatal mortality from pneumonia fell from 1.6. to 1.1 per 1000 while 
neonatal mortality from influenza remained constant at 0.2 per 1000 (US Vital Statistics).   13
income). The third section presents race-specific results and the fourth discusses findings 
from additional falsification tests. All estimates are presented by gender. 
 
5.1. Main Results 
Refer  Table 2 where each cell reports estimates of the coefficient on 
postt*base_pneumonias from a separate regression. The rows denote the outcome variables and 
the columns different sets of control variables. We report estimates with a growing set of 
controls. We find positive and statistically significant impacts of exposure to sulfa on years 
of schooling for men. This result is remarkably robust to successive inclusion of post*base for 
mortality rates from the control diseases (which include maternal mortality), state 
socioeconomic and infrastructure characteristics, state specific linear time trends, and census 
region times birth year fixed effects. The specification with all of these controls implies a 
post-sulfa gain of 0.19 in years of schooling associated with shifting the pre-sulfa pneumonia 
death rate from the 75
th to the 25
th percentile of its distribution (i.e., from 1.18 to 0.92 deaths 
per 1,000).
10  
Men also exhibit post-sulfa improvements in the other indicators. The post-sulfa 
improvement flowing from a change in the pre-sulfa pneumonia death rate from the 75
th to 
the 25
th percentile of its distribution is 2.8% for family income, 0.7 percentage points (up) in 
the probability of being employed, and 0.62 percentage point (down) in the probability of 
reporting a disability limiting or preventing work. These estimates are all from column (5), 
the specification with the most comprehensive set of controls. For schooling, income and 
disability, we find effects of a similar magnitude for women in the specifications with birth 
state and birth year fixed effects and control diseases (columns 1 and 2). These estimates are 
diminished and driven to insignificance by the inclusion of state socioeconomic variables 
and state specific trends. However, as we shall see below, once we invoke a third difference 
                                                 
10 We do not find compelling evidence of a relationship between exposure to lower maternal 
mortality rates and long-run outcomes. For men, the estimates on post*base_MMR are negative for 
schooling, income and employment, and positive for disability. These estimates are not robust to 
specification. For women, the estimates are small, positive, and insignificant for all four of these 
outcomes. The results suggest that either reductions in maternal mortality did not change parental 
investments in a way that led to long-run changes in health and socioeconomic status, or that the 
investment effects of maternal mortality declines through the pathways discussed earlier in the text 
offset each other.    14
in the specification, women exhibit improvements in schooling, employment and income 
that are robust to the richest set of controls. 
Figures 3 and 4 present plots of the coefficients on birth year*base. The coefficients for 
men show trend breaks around 1937, consistent with the introduction of sulfa drugs. 
Interestingly, for most of the variables, the effect sizes climb in magnitude over the period 
1937-1939, which is consistent with the fact that the earliest sulfa drugs were less effective in 
treating pneumonia than sulfapyridine, which was available in 1938 and became widely used 
by 1939. In line with the results from Table 2, the sharp sulfa trend breaks are either more 
muted or non-evident for the estimates for women
11. There is no evidence of trend breaks in 
years other than those associated with the introduction of sulfa. In particular, the coefficients 
for men prior to 1937 hover around zero indicating that the returns to sulfa exposure were 
likely limited to the birth year.
12 
 
5.2. Additional Disability Variables 
We have so far analyzed self-reported work-related disability. This measure will carry 
“justification bias” if the welfare regime encourages individuals to invent or exaggerate 
disability (Autor & Duggan, 2003). While the importance of justification bias is contentious, 
we investigate additional measures of disability that are unrelated to work participation and 
so may serve as cleaner measures of health. These are indicators for whether individuals 
reported experiencing difficulties with basic physical and cognitive tasks because of physical 
or mental conditions, available only in the 2000 census.  
The results are in Table 3. For men, columns (1) and (2) show negative estimates for 
cognitive and physical disability, with coefficients for the former being statistically 
significant. For cognitive difficulty, the estimated magnitudes are largest in magnitude for the 
                                                 
11 Indeed, the generally uptrending coefficients and the lack of a sharp trend break in 1937 is 
consistent with our finding large, significant coefficients in the specifications with fewer controls and 
with these effects being obliterated with the inclusion of birth state-specific time trends. As discussed 
in section 3, it is unclear whether the estimates with or without trends are more reliable. However 
comparing Tables 2 and 7 suggests sustained and robust improvements for women. 
12 This is consistent with pre-sulfa pneumonia mortality and morbidity rates being higher by a large 
margin amongst infants (Britten 1942). The age distribution of influenza and pneumonia during the 
1918 influenza epidemic appears to have been unusual (e.g. Collins 1931) and is in any case different 
from that in endemic cases. While endemic infection is concentrated at the two tails of the age 
distribution, the 1918 epidemic infection rates peaked amongst women of child-bearing age. As a 
result, the long run effects identified in Almond (2006) arise from foetal exposure to maternal 
infection; there is no evidence of long run impacts associated with birth year exposure.    15
specifications with birth state specific time trends: a move from the 75
th to 25
th percentile of 
the pre-sulfa baseline pneumonia mortality distribution is associated with a 0.71 percentage 
point post-sulfa decrease in the probability of reporting a cognitive disability. There are no 
significant sulfa impacts on the risk of physical disabilities. We are unable to detect any 
lowering of cognitive or physical disability amongst women on account of sulfa. Rather, for 




5.3. Race Specific Effects 
Refer Tables 4-6. The results for white men and women mirror those for all men and all 
women. It is noteworthy that the coefficients for black and white men and women in Tables 
4 and 5 are similar (and insignificantly different from one another) in column 1.  
However the coefficients for the black population are imprecisely estimated and tend 
to become smaller upon inclusion of controls from column 2 onwards. Some specifications 
suggest stronger impacts on income for black people. It may be that the black population 
accessed sulfa later than the white population, in which case “post” may need to be 
redefined for the former. To investigate this possibility we estimated the more general model 
in which we do not impose the definition of post but allow “base” to take year-specific 
coefficients (coefficient plots for blacks corresponding to Figures 3 and 4 are available in the 
online appendix). We find no evidence of a trend break in outcomes for black men and 
women in either 1937 or a subsequent date.  
Table 6 presents results for the additional disability variables. Black men experienced 
larger reductions in cognitive disability from sulfa drug exposure than white men and this 
finding is fairly robust to specification. Moving from the 75
th to the 25
th percentile of the 
baseline pneumonia mortality distribution is associated with a 1.03-1.45 percentage point 
decrease in the probability that black men report a cognitive disability. Exposure to sulfa also 
had larger impacts on physical disability for blacks, though this is attenuated with the 
inclusion of additional controls and trends. The results for black women are similar to results 
for white women.  
                                                 
13 It is possible that the positive coefficients that emerge with stronger controls in these 
specifications, and perhaps those reported in earlier tables, are a spurious artifact of over-controlling 
for unobservables. However, we are unable to establish this.   16
A reason that the estimates for blacks are so imprecisely determined may be that the 
state-level pneumonia mortality rate is a poor measure of pneumonia mortality for blacks 
since they are, on average, 10% of the population. If the ratio of white to black mortality 
rates were constant over time then this would not be so much of an issue. However it is 
plausible that the ratio varies. We therefore re-estimated the model utilizing race-specific 
state mortality rates (these data combine all non-white races).  Since some states have very 
small populations and this increases the potential for measurement error, we followed 
Jayachandran, et al (2010) and only examined data for those states in which blacks were 
more than 10% of the population and we further limited the sample to states with non-white 




5.4. Additional Robustness Checks 
We conducted several additional falsification tests to address the robustness of our 
results. The first set of checks involved controlling for mean reverting shocks. Our concern 
here is that some negative shock in the years preceding the arrival of sulfa reduced the 
human capital attainment of the affected cohorts. With the resolution of the shock, these 
outcomes reverted back to the mean thus producing what we may mistakenly be interpreting 
as a sulfa effect. In order to control for mean reversion, we use the strategy employed in 
Bleakley (2007) and include controls for post  interacted with the average value of the 
outcome of interest in each birth state for the pre-sulfa cohorts. The results, shown in Table 
7, suggest that the inclusion of controls for mean reversion does little to alter our substantive 
conclusions
15.  
We estimate “triple-difference” models as an additional test. As explained in section 
3, the idea here is to exploit the epidemiology of pneumonia. Differencing across age of 
exposure with respect to an intervention (sulfa) at a fixed time will remove any 
unobservables that influenced human capital acquisition for the post-sulfa cohort. We used 
                                                 
14 These estimates are in the online appendix. The race-specific mortality data are likely to be flawed 
to the extent that mortality reporting for non-whites was more prone to underreporting, 
misclassification or other measurement bias. However any such reporting bias will transmit to the 
race-averaged data used in the main analysis.   
15 While the coefficient on (all) men’s education drops appreciably with the inclusion of the mean 
reversion controls, the estimates that distinguish white and black men are robust.    17
cohorts born between 1915-1927 as controls for the treated 1937-1943 cohorts examined 
above. We divided the control cohorts into those who turned 15 during the sulfa drug era 
(that is, post = 1 for cohorts born between 1922-1927) and those who were this age before 
(post = 0 for the 1915-1921 birth cohorts).
16  
The results of the “triple difference” analysis are presented in Table 8. These are 
estimates with the richest set of controls, corresponding to column 5 in Table 2. For men, 
the estimates are remarkably similar in magnitude and significance to those in Table 2. 
Interestingly, the results for women now show large positive estimates for schooling, family 
income and probability of employment, all of which are significant. We also now find large 
impacts for all four outcomes of interest for black men, though only the work disability 
estimate is statistically significant. Overall, results for white men are robust to this extension 
and results for white women and blacks improve. 
Finally we summarise a number of other checks we conducted; results are available 
on request. If we define post at 1936, we find almost no significant impacts. If we define it at 
1938 then, consistent with diffusion from 1937, we estimate similar and slightly larger 
coefficients. The coefficients are in general robust to truncating the sample window at 1941 
(war and penicillin) and also to using a narrower window, starting 1934. There is some 
concern in the literature that the 2000 census microdata sample used in this paper may be 
subject to inaccuracies in age reporting (Alexander, Davern, & Stevenson, 2010). While this 
problem primarily pertains to those over the age of 65, all of whom were born at least two 
years prior to the start of the sulfa era, we still assessed whether our results remained the 
same if the 2000 census was excluded. We indeed find that the substantive results are 
unchanged (results not shown here).  
 
5.5. Discussion 
Heterogeneity in impacts by gender and race 
Section 3 set out reasons that we may expect gender and race heterogeneity. Here we 
consider our findings in view of the priors set out earlier. The baseline estimates (Table 2) 
suggest stronger impacts for men for all outcomes. The triple difference estimates in Table 8 
we find significant but smaller gains in schooling and income for women. We identify larger 
absolute gains in employment for women but these are probably related to more 
                                                 
16 We thank Tania Barham for suggesting this.    18
contemporary changes in gender-specific returns to education and marriage. Thus the 
findings suggest that men benefited more from early life exposure to sulfa than women, 
consistent with the biological hypotheses set out in section 3 above, in particular with the 
fact that they face a (25%) higher probability of contracting pneumonia in infancy.  
By the same token, since blacks faced a (100%) higher risk of contracting pneumonia 
than whites, we may have expected to see larger gains amongst them. But we don’t. 
Jayachandran, et al (2010) provide evidence that blacks benefited less from sulfa drugs in 
terms of percentage declines in mortality from pneumonia and other sulfa-treatable diseases. 
However, (a) they still did benefit and (b) the absolute decline in pneumonia mortality rates 
was in fact larger for blacks. Both of these patterns are shown in Figure 5. The evidence that 
blacks drew a short run benefit from sulfa suggests that they did access sulfa drugs – despite 
being poorer and facing weaker access to hospitals and prescriptions. This ties in with the 
evidence presented in section 2 that sulfa drugs were widely used for outpatient care. 
Overall, the idea of barriers to sulfa uptake cannot on its own explain our failure to identify a 
long run benefit for blacks.  
An explanation that suggests itself is that blacks encountered barriers to translating 
improved health endowments in infancy into human capital and socioeconomic returns in 
later life. For example, it is well known that differentials in wages, school quality and returns 
to education between blacks and whites were more marked prior to the Civil Rights Act of 
1965 (Donohue & Heckman, 1991). Limited access to quality schools and training 
institutions alongside a discriminatory labor market may have depressed expected returns to 
human capital investment to the point that they were not been deemed worthwhile. This 
hypothesis is supported by the fact that the estimates for reductions in cognitive disability 
post-sulfa are larger in magnitude for black vis-à-vis white men (as are reductions in work 
disability in the specification in Table 8) while gains in schooling and employment are 
smaller.
17. 
Selection, participation and size of effects   
                                                 
17 Another piece of supporting evidence, though more tenuous, is that the estimated income gains for 
black men and women are larger than those for whites in several of our specifications. This suggests 
that blacks may have been able to use sulfa-driven health or cognitive endowments in the 
marketplace to secure higher earnings as they arrived on the labour market in the post-Civil Rights 
Act era, although on margins that did not involve returns to schooling, their schooling having been 
determined prior to the Civil Rights Act.   19
In this section we discuss a number of reasons why the estimated magnitudes of the 
long run impacts discussed earlier are likely to under-state the positive impacts of sulfa 
drugs. First, the estimates describe averages across the entire population. To assess the long-
run returns of sulfa drugs accruing to those who actually contracted the disease, we would 
have to divide our estimates by the fraction of infants with pneumonia. As discussed in 
section 2, infection or prevalence rates are difficult to pin down due to the paucity of and 
limitations in surveillance data from the pre-sulfa drug era. However, if we take a case rate of 
25 per 100 child-years to approximate the situation in today’s developing countries, our 
results for males suggest a 0.41-0.77 increase in years of schooling, a 4.1-11.1% increase in 
family income, a 1.63-2.79% increase in the probability of employment, and a 2.49-3.03% 
decrease in the probability of reporting a work preventing disability for individuals who 
actually had pneumonia as a result of the arrival of sulfa. Clearly, this is a rough calculation: it 
assumes that sulfa drugs only led to reductions in the severity of pneumonia without 
affecting the incidence rate or the distribution of who actually contracted the disease; it also 
assumes no within-cohort spillover effects from those afflicted by pneumonia to those that 
were not.  
The previous discussion concerns the infection rate in the population. Conditional 
upon infection, access to and use of sulfa drugs to treat pneumonia was probably not 
universal. In other words, we recover an intent-to-treat effect which will be smaller than the 
average effect of the treatment on the treated. The cost of a complete course was $28-$100 
(in 2008 US $) or $4.3 per patient per day. While seemingly inexpensive, recurrent or lengthy 
bouts of infection may have conferred non-trivial costs for the poor. Moreover, some people 
may have elected not to use sulfa as it was a new drug, the side effects of which were initially 
unknown and once known, unpalatable.
18 
Mortality selection will tend to bias our estimates towards zero since frailer children 
were probably more likely to succumb to pneumonia than their healthier counterparts. With 
                                                 
18 Sulfonamides have the potential to cause a variety of untoward reactions, including urinary tract 
disorders, haemopoietic disorders, porphyria and hypersensitivity reactions. When used in large 
doses, they may cause a strong allergic reaction, e.g. Stevens Johnson syndrome and toxic epidermal 
necrolysis (also known as Lyell syndrome). It is estimated that about 3% of the general population 
have adverse reactions when treated with sulfonamide antimicrobials (Wikipedia). 
   20
the advent of sulfa, more of these children would survive past childhood and these innately 
less health individuals are likely to be less productive and healthy as adults (Bozzoli, Deaton, 
& Quintana-Domeque, 2009). That said, we expect this bias to be small since pre-
intervention death rates amongst infants were around 1% (Britten, 1942; Councell, 1963). A 
less recognized mechanism running from changes in the mortality environment in early life 
to later life attainments operates within family. To the extent that the index individual is less 
likely to have lost a sibling to pneumonia mortality, parental investments in the index child 




This study provides the first evidence of long-term scarring effects of early life 
exposure to (endemic) pneumonia, effects that we show are not only discernible at the 
population level but large. It also offers some of the first estimates of the long-run 
socioeconomic and health returns to medical technology, in particular antibiotics. We 
identify robust impacts for white men of sulfa-induced reductions in pneumonia risk in 
infancy on adulthood indicators of education, employment, income and work-related 
disability risk. White women exhibit some impressive improvements in socioeconomic 
outcomes that are sensitive to state trends in a double difference but robust in a triple 
difference specification. Estimates for African-Americans are poorly determined, making it 
hard to rest a firm story on them. While coefficients for socioeconomic outcomes are 
smaller, there is some evidence of a substantial reduction in the risk of cognitive disability 
and work disability for black men born after the arrival of sulfa drugs as well as some 
evidence of income gains for black men and women. In our future work we propose to 
investigate a richer set of outcomes for the first generation as well as second generation 
outcomes. 
These results are important for developing countries where acute respiratory 
infections are the leading cause of early childhood mortality. They point to the need for 
greater research and policy focus on the causes and consequences of early life pneumonia, as 
well as strategies to prevent and treat this disease in these areas. They indicate that medical 
technology, especially innovations targeting infants, may generate returns throughout the life 
cycle. A recent community-based intervention in India that involved treatment of   21
pneumonia in children aged 0-4 years with co-trimoxazole showed a case-fatality rate of 
0.8% in the treatment area compared with 13.5% in the control area. The cost of co-
trimoxazole was US $0.025 per child per year or $2.64 per child saved (Bang et al. 1990). 
Evidence of this nature is still scarce and useful. However the literature fails to account for 
the longer-run returns to antibiotic treatment that work through lowering the duration and 
severity of illness in the population that survives pneumonia.  
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Notes:  Total mortality from influenza and pneumonia for all age groups. The dashed-
vertical line represents the year in which sulfa antibiotics first became available in the United 
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1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943
Birth Year
% Work Limiting Disability
  
Notes: Each point reflects the estimate on the interaction between the marked birth year 
and  BaseRatePNA. All models include birth state and birth year fixed effects, 
Post*BaseRate(Control Diseases), and birth state X birth year macroeconomic and infrastructure 
variables (i.e., the same control vector as used in Column 3 of Table 2). The vertical line 
denotes the year sulfa drugs became available in the United States (agents more efficacious 
against pneumonia became available in 1938). See the notes for Table 2 for further details.  
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Table 1 – Sample Descriptives 
Census Variables Men Women White Men White Women Black Men Black Women
Schooling 12.64 (0.87) 12.29 (0.67) 12.79 (0.72) 12.40 (0.59) 11.20 (0.84) 11.48 (0.70)
Family Income 63667.42 (12498.54) 56367.86 (11148.51) 65694.67 (11238.07) 58713.07 (9420.62) 45060.67 (6847.58) 38527.27 (5876.59)
% Employed 73.98 (21.49) 53.36 (16.27) 75.16 (21.37) 53.45 (16.17) 63.22 (19.48) 52.73 (16.99)
% Work Disability 13.36 (5.19) 12.22 (5.07) 12.69 (4.51) 11.24 (3.92) 19.54 (6.67) 19.67 (6.47)
% Cognitive Difficulty 6.02 (2.86) 5.42 (2.46) 5.63 (1.78) 4.84 (1.52) 9.83 (3.39) 10.09 (3.34)
% Physical Difficulty 18.37 (5.12) 18.79 (5.68) 17.65 (4.49) 17.52 (1.52) 25.39 (5.55) 28.95 (5.74)
Birth State Baseline Mortality Rates (Per Thousand, N = 48 States)
Pneumonia 1.06 (0.19)
Under-2 Diarrhea 8.22 (5.65)
Maternal Mortality  6.34 (1.24)
Tuberculosis 0.64 (0.37)
Heart Disease 2.09 (0.64)
Cancer 0.96 (0.31)
Birth State X Birth Year Socioeconomic Variables (N = 669)
Income Per Capita 544.72 (274.63)
Hospitals Per 1,000 0.067 (0.042)
Physicians Per 1,000 1.21 (0.36)
Schools Per 1,000 2.52 (1.90)
Educational Spending Per Capita 87.04 (52.09)
Notes:
-Figures provided are means, with standard deviations in parentheses
-See main text and the Data Appendix for details on variable definitions and construction
-The means for the census variables are based on the 2019930 men, 2137468 women, 1821471 white men, 198459 black men, 
1897973 white women and 249495 black women born between 1930 and 1943 who are part of the 1980, 1990 and 2000 5% US census
samples available from IPUMS.USA. Note that for the regressions, cell-level means are used as observations instead of unit record
data
-Census family income figures reflect 2000 dollars
-Baseline mortality rates reflect average mortality rates for each birth state over the period 1930-1936. Rates for pneumonia, 
tuberculosis, heart disease and cancer reflect deaths per 1,000 total population. Diarrheal rates are computed per 1,000 live births
















Table 2 – Main Results for Schooling, Income, Employment and Disability by 
Gender   31
(1) (2) (3) (4) (5)
Men
Schooling 0.399*** 0.297*** 0.332*** 0.555*** 0.742***
(N = 1154) (0.105) (0.0921) (0.112) (0.0908) (0.147)
Ln(Family Income) 0.0387*** 0.0362*** 0.0493*** 0.0753*** 0.107***
(N = 3405) (0.0138) (0.0125) (0.0152) (0.0185) (0.0200)
% Employed 1.565*** 1.241** 2.441*** 2.531** 2.676
(N = 3405) (0.573) (0.523) (0.566) (1.102) (1.743)
% Work Limiting Disability -2.918*** -2.088*** -1.448*** -1.013 -2.394***
(N = 3405) (0.599) (0.485) (0.491) (1.036) (0.803)
Women
Schooling 0.410*** 0.363*** 0.174 0.00201 -0.0219
(N = 1161) (0.0848) (0.0781) (0.111) (0.131) (0.172)
Ln(Family Income) 0.0545*** 0.0479*** 0.0325** -0.0140 0.0326
(N = 3448) (0.0147) (0.0139) (0.0146) (0.0180) (0.0253)
% Employed -1.018 -0.783 1.983** 0.561 -0.624
(N = 3448) (0.651) (0.620) (0.782) (1.170) (1.564)
% Work Limiting Disability -2.487*** -1.583*** 0.147 1.263 1.901**
(N = 3448) (0.691) (0.539) (0.561) (0.769) (0.893)
Controls
Birth State, Birth Year FE Yes Yes Yes Yes Yes
Post*BaseRate(Control Diseases) No Yes Yes Yes Yes
Birth State X Birth Year Macro No No Yes Yes Yes
Birth State Linear Trends No No No Yes Yes
Birth Census Region X Birth Year FE No No No No Yes
Notes
-*** - p<0.01, ** - p<0.05, * - p<0.10
-Robust standard errors, corrected for clustering at the birth state level, in parenthesis
-Each estimate is from a different regression and represents the estimate on Post*BaseRatePNA
-N refers to the number of Birth State X Birth Year X Race X Gender X Census Year cells
-Each cell is weighted by its population in the regression analysis; unweighted regressions
produce substantively similar results
-The outcome variables Schooling, Ln(Family Income), % Employed and % Work Limiting
Disability are discussed in the main text as well as in the Data Appendix
-BaseRate(Control Diseases) includes pre-sulfa birth state averages for maternal mortality,
heart disease, cancer, under 2 diarrheal, and tuberculosis mortality
-"Birth State X Birth Year Macro" includes controls for logged state per capita income
per capita educational expenditures, and per capita school buildings, hospitals, and physicians
by birth state and birth year  
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Table 3 – Additional Disability Variables by Gender 
(1) (2) (3) (4) (5)
Men
% Cognitive Disability -1.40** -0.996* -0.499 -2.28* -2.74
(N = 1124) (0.601) (0.552) (0.706) (1.26) (1.70)
% Physical Disability -1.23 -0.960 -0.687 -0.141 1.97
(N = 1124) (0.980) (1.10) (1.29) (2.58) (2.44)
Women
% Cognitive Disability -0.903 -0.229 1.32* 2.09* 0.818
(N = 1142) (0.605) (0.523) (0.707) (1.16) (1.17)
% Physical Disability -1.04 -0.441 0.695 3.32** 3.45
(N = 1142) (0.886) (0.806) (0.971) (1.48) (2.06)
Controls
Birth State, Birth Year FE Yes Yes Yes Yes Yes
Post*BaseRate(Control Diseases) No Yes Yes Yes Yes
Birth State X Birth Year Macro No No Yes Yes Yes
Birth State Linear Trends No No No Yes Yes
Birth Census Region X Birth Year FE No No No No Yes
Notes
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Table 4 – Results for Schooling, Income, Employment and Disability for White Men 
and Women 
(1) (2) (3) (4) (5)
White Men
Schooling 0.401*** 0.326*** 0.416*** 0.607*** 0.868***
(N = 655) (0.107) (0.0929) (0.114) (0.111) (0.177)
Ln(Family Income) 0.0351** 0.0335** 0.0497*** 0.0647*** 0.106***
(N = 1965) (0.0146) (0.0129) (0.0155) (0.0226) (0.0298)
% Employed 1.421** 1.157* 2.449*** 2.110* 2.770
(N = 1965) (0.636) (0.576) (0.612) (1.251) (2.141)
% Work Limiting Disability -3.161*** -2.346*** -1.689*** -1.249 -3.159***
(N = 1965) (0.650) (0.546) (0.567) (1.087) (0.821)
White Women
Schooling 0.409*** 0.393*** 0.264*** 0.00563 -0.0391
(N = 1161) (0.0854) (0.0760) (0.0932) (0.147) (0.227)
Ln(Family Income) 0.0522*** 0.0479*** 0.0359** -0.0241 0.0222
(N = 1965) (0.0163) (0.0151) (0.0163) (0.0208) (0.0358)
% Employed -1.536** -1.193* 1.936** 1.199 -0.0708
(N = 1965) (0.681) (0.672) (0.820) (1.160) (1.742)
% Work Limiting Disability -2.736*** -1.863*** -0.111 1.302 2.266*
(N = 1965) (0.761) (0.574) (0.576) (0.865) (1.229)
Controls
Birth State, Birth Year FE Yes Yes Yes Yes Yes
Post*BaseRate(Control Diseases) No Yes Yes Yes Yes
Birth State X Birth Year Macro No No Yes Yes Yes
Birth State Linear Trends No No No Yes Yes
Birth Census Region X Birth Year FE No No No No Yes
Notes




   34
Table 5 – Results for Schooling, Income, Employment and Disability for Black Men 
and Women 
(1) (2) (3) (4) (5)
Black Men
Schooling 0.380 -0.0534 -0.411* -0.0503 -0.0707
(N = 499) (0.302) (0.240) (0.235) (0.197) (0.224)
Ln(Family Income) 0.0792 0.0537 0.00696 0.121 0.0337
(N = 1439) (0.0535) (0.0461) (0.0558) (0.116) (0.101)
% Employed 3.183 1.438 -2.178 1.625 -1.764
(N = 1440) (2.687) (2.593) (2.408) (4.067) (3.500)
% Work Limiting Disability -0.187 1.023 -0.579 -1.035 0.251
(N = 1440) (1.547) (1.335) (1.696) (3.807) (4.384)
Black Women
Schooling 0.415 0.0783 -0.488 -0.194 -0.279
(N = 506) (0.345) (0.288) (0.369) (0.305) (0.357)
Ln(Family Income) 0.0760* 0.0358 0.0115 0.0629 0.110
(N = 1483) (0.0418) (0.0422) (0.0478) (0.0737) (0.101)
% Employed 3.786** 3.210** 0.404 -4.836 -2.977
(N = 1483) (1.558) (1.350) (2.219) (2.979) (2.770)
% Work Limiting Disability -0.171 0.637 1.718 1.607 -1.302
(N = 1483) (1.530) (1.719) (1.734) (3.149) (3.151)
Controls
Birth State, Birth Year FE Yes Yes Yes Yes Yes
Post*BaseRate(Control Diseases) No Yes Yes Yes Yes
Birth State X Birth Year Macro No No Yes Yes Yes
Birth State Linear Trends No No No Yes Yes
Birth Census Region X Birth Year FE No No No No Yes
Notes
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Table 6 – Additional Disability Variables by Gender X Race Groups 
(1) (2) (3) (4) (5)
White Men
% Cognitive Disability -1.07 -0.649 -0.0209 -1.67 -1.44
(N = 655) (0.658) (0.630) (0.755) (1.37) (1.92)
% Physical Disability -0.932 -0.592 -0.205 0.169 2.31
(N = 655) (1.03) (1.16) (1.38) (2.86) (2.72)
White Women
% Cognitive Disability -1.09* -0.453 1.02 1.65 0.483
(N = 655) (0.626) (0.521) (0.654) (1.19) (1.59)
% Physical Disability -0.891 -0.340 1.49 3.60*** 4.10*
(N = 655) (0.893) (0.846) (0.978) (1.32) (2.18)
Black Men
% Cognitive Disability -5.26*** -5.59*** -4.67** -5.23 -3.97
(N = 469) (1.55) (1.85) (2.23) (6.16) (7.49)
% Physical Disability -4.75* -6.07** -0.451 0.149 2.17
(N = 469) (2.54) (2.95) (4.27) (6.29) (9.81)
Black Women
% Cognitive Disability 0.935 1.93 4.24 1.58 -0.195
(N = 487) (1.77) (1.75) (2.68) (3.72) (3.77)
% Physical Disability -2.50 -1.63 0.367 10.6 4.17
(N = 487) (3.13) (3.54) (3.33) (9.88) (9.41)
Controls
Birth State, Birth Year FE Yes Yes Yes Yes Yes
Post*BaseRate(Control Diseases) No Yes Yes Yes Yes
Birth State X Birth Year Macro No No Yes Yes Yes
Birth State Linear Trends No No No Yes Yes
Birth Census Region X Birth Year FE No No No No Yes
Notes




   36
Table 7 – Specifications with Mean Reversion Controls 
(1) (2) (3) (4)
Schooling Ln(Family Income) % Employed % Work Disability
All Men 0.351* 0.0999*** 2.605 -1.218
(0.189) (0.0231) (1.774) (0.923)
All Women -0.403* 0.0267 -0.983 2.858***
(0.206) (0.0281) (1.515) (0.948)
White Men 0.756*** 0.0696* 2.855 -3.196***
(0.214) (0.0372) (2.143) (0.887)
White Women -0.104 0.0521 -0.301 2.691**
(0.302) (0.0370) (1.734) (1.286)
Black Men -0.0728 0.0157 -2.046 0.0472
(0.239) (0.101) (3.674) (4.274)
Black Women -0.375 0.0647 -3.627 -1.564
(0.340) (0.107) (2.942) (3.472)
Notes
-*** - p<0.01, ** - p<0.05, * - p<0.10
-Robust standard errors, corrected for clustering at the birth state level, in parenthesis
-Each estimate is from a different regression and reflects the coefficient on Post*BaseRatePNA.
-These models control for Post*BaseRate(Outcome) in order to control for mean reverting shocks that are jointly
correlated with trends in pneumonia and the outcomes
-All models include the controls in Column 5 of Table 2. Refer to the Table 2 notes for further details.
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Table 8 – Triple Difference Specifications 
(1) (2) (3) (4)
Schooling Ln(Family Income) % Employed % Work Disability
All Men 0.800*** 0.107*** 2.676 -2.394***
(0.219) (0.0200) (1.743) (0.803)
All Women 0.467** 0.0603*** 4.314*** -0.410
(0.222) (0.0180) (1.159) (1.219)
White Men 0.851*** 0.131*** 1.578 -0.993
(0.225) (0.0256) (1.188) (1.211)
White Women 0.581*** 0.0441** -0.164 0.802
(0.197) (0.0193) (1.196) (0.689)
Black Men 0.430 0.0875 5.418 -8.392***
(0.655) (0.0826) (3.431) (2.328)
Black Women -0.479 0.0621 0.233 -0.830
(0.742) (0.0711) (2.674) (3.553)
Notes
-*** - p<0.01, ** - p<0.05, * - p<0.10
-Robust standard errors, corrected for clustering at the birth state level, in parenthesis
-Each estimate is from a different regression and represents the estimate on the triple difference
Post*BaseRatePNA*Treated, where Treated = 1 refers to those who were infants during the period 1932-1943
The control cohort includes those who turned 10 during this same period. For the control cohort, Post = 1
if the cohort turned 10 years old in 1937 or thereafter. 
-All models include controls for Post*BaseRatePNA, Post*Treated, Treated*BaseRatePNA, birth state and 
birth year fixed effects, Post*BaseRate(Control Diseases), birth state specific linear time trends, and census
 region of birth X birth year fixed effects
-Refer to main text for further details; refer to Table 2 notes for details regarding the control variables.















Outcomes – These were all taken from the 1980 5%, 1990 5% and 2000 5% United States 
Census Microdata samples (available via IPUMS-USA, http://usa.ipums.org/usa/). These 
data are publicly available via the Integrated Public Use Microdata Series – USA project 
(Ruggles, Alexander, Genadek, Goeken, Schroeder, & Sobek, 2010). We aggregated all data 
into birth state X birth cohort X race (white and other) X gender X census year cells. Data 
on the 2,019,930 men, 2,137,468 women, 1821,471 white men, 198,459 black men, 1,897,973 
white women and 248,495 black women in the three census samples who were born 
between 1930 and 1943 (the period of interest in the study) were used to create cell level 
means. 
 
Schooling  – Represents the highest grade of schooling completed. This variable was 
constructed using the IPUMS variable HIGRADE. Since schooling was likely completed 
before the age of 30 for most sample individuals, we used only the 1980 census data for this 
variable. 
 
Logged Total Family Income – From the IPUMS variable FTOTINC. Describes the (nominal) 
total pre-tax money income earned by the respondent’s family unit in the previous calendar 
year. 
 
Employed  - Uses the IPUMS variable EMPSTAT, which distinguishes between current 
employment, unemployment and not being in the labor force. For each individual, we set 
employment = 1 if the individual reports current employment and 0 otherwise. 
 
Work Limiting Disability – The IPUMS variable DISABWRK Indicates a physical or mental 
health condition that causes difficulty working, limits the amount or type of work, or 
prevents working altogether. The disability cannot be transient (e.g., pregnancy) and must 
have been present for at least six month prior to survey. We coded any limitation in the 
ability to work (either certain limitations or the inability to work altogether) as representing 
disability.   39
 
Cognitive Disability – From the IPUMS variable DIFFREM, which denotes whether an 
individual has difficulty with cognitive tasks due to a physical or mental illness. This variable 
is only available in the 2000 census. 
 
Physical Disability – From the IPUMS variable DIFFPHYS. Denotes if the respondent has a 
condition that limits basic tasks of daily living that involve movement (walking, running, 
lifting, etc). This variable is only available in the 2000 census.  
 
Baseline Pneumonia Rates and Disease Variables – State X Year data on pneumonia, 
under-2 diarrheal, heart disease, cancer, and tuberculosis mortality, as well as the maternal 
mortality ratio, were taken from various volumes of the US Vital Statistics (Grove, 1968; 
Linder, 1947; United States Bureau of the Census, 1930-1943). We also made use of US Vital 
Statistics data collected by Grant Miller (http://www.nber.org/data/vital-statistics-deaths-
historical/) and Seema Jayachandran, Adriana Lleras-Muney, and Kimberly Smith 
(http://www.aeaweb.org/articles.php?doi=10.1257/app.2.2.118). We used the State X Year 
data to create state-specific baseline rates for each disease by averaging mortality rates 
between 1930 and 1936.  
Of note, for several of the years in the period 1930-1943, pneumonia mortality 
counts were combined with influenza mortality counts. As such, we follow Jayachandran, et 
al (2010) and work with a combined pneumonia/influenza mortality rate. As noted in the 
main text, influenza mortality rates remained stable during the study period and, prior to 
sulfa, accounted for ~25% of the combined mortality rate. 
In addition, we also used Race X State X Year mortality figures for pneumonia and 
several other diseases. We thank Adriana Lleras-Muney for providing use these data, which 
were originally taken from yearly US Vital Statistics volumes 
(http://www.cdc.gov/nchs/products/vsus.htm).  
 
Socioeconomic Characteristics and Infrastructure Variables – State X Year data on 
logged state per capita income were taken from the Bureau of Economic Analysis website 
(http://www.bea.gov/regional/spi/). Data on the number of schools, doctors, hospitals, 
and educational expenditures per capita were taken from Adriana Lleras-Muney’s website   40
(http://www.econ.ucla.edu/alleras/research/data.html). These data were originally collected 
from various volumes of the Biennial Survey of Education (schools and expenditures) and the 
American Medical Association’s American Medical Directory (doctors and hospitals). We used 
linear interpolation for each state to calculate education and health infrastructure values for 
1940-1943, as Lleras-Muney’s data was only collected through 1939. 
 
 